<DOC>
	<DOC>NCT02428010</DOC>
	<brief_summary>Study to evaluate the safety and performance of the Twelve TMVR System</brief_summary>
	<brief_title>Twelve Transcatheter Mitral Valve Replacement (TMVR) Pilot Study</brief_title>
	<detailed_description>The study is a prospective, multi-center, non-randomized trial to evaluate the safety and performance of the Twelve TMVR System in very high risk patients with severe, symptomatic mitral regurgitation.</detailed_description>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Key Severe mitral regurgitation (MR Grade 34+) Symptomatic mitral regurgitation (NYHA Class IIIV) Transapical access deemed feasible by the treating physician Native mitral valve geometry and size compatible with the Twelve TMVR Key Left ventricular ejection fraction (LVEF) &lt; 20 Evidence of intracardiac mass, thrombus, or vegetation Prior valve surgery or need for other valve surgery Prior stroke within 4 weeks Need for coronary revascularization History of, or active, endocarditis Renal insufficiency (Creatinine &gt; 2.5 mg/dL)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>